Menu
Back to User profile » Dr Ming-zhi Zhang
Papers published by Dr Ming-zhi Zhang:
Identification and Validation of Anoikis-Related Signatures for Predicting Prognosis in Lung Adenocarcinoma with Machine Learning
Wang Q, Sun N, Zhang M
International Journal of General Medicine 2023, 16:1833-1844
Published Date: 16 May 2023
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
Du L, Zhang L, Li L, Li X, Yan J, Wang X, Fu X, Sun Z, Zhang X, Li Z, Wu J, Yu H, Chang Y, Zhou Z, Nan F, Wu X, Tian L, Zhang M
OncoTargets and Therapy 2020, 13:7189-7197
Published Date: 27 July 2020
Primary Causes of Death in Patients with Non-Hodgkin’s Lymphoma: A Retrospective Cohort Study
Mei M, Wang Y, Song W, Zhang M
Cancer Management and Research 2020, 12:3155-3162
Published Date: 6 May 2020
High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases
Li J, Liu X, Yao Z, Zhang M
Cancer Management and Research 2020, 12:1903-1912
Published Date: 13 March 2020
Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M
Drug Design, Development and Therapy 2020, 14:275-284
Published Date: 22 January 2020
CircCDYL Serves as a New Biomarker in Mantle Cell Lymphoma and Promotes Cell Proliferation
Mei M, Wang Y, Wang Q, Liu Y, Song W, Zhang M
Cancer Management and Research 2019, 11:10215-10221
Published Date: 3 December 2019
Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
Liu X, Shang Y, Li L, Zhang X, Li Z, Zhang M
Cancer Management and Research 2019, 11:8277-8284
Published Date: 9 September 2019
Clinical features and prognostic factors of primary bone marrow lymphoma
Wang G, Chang Y, Wu X, Li X, Li L, Zhang L, Fu X, Sun Z, Zhang X, Zhang M
Cancer Management and Research 2019, 11:2553-2563
Published Date: 29 March 2019
Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
Xue W, Li W, Zhang T, Li Z, Wang Y, Qiu Y, Wang Y, Chen C, Fu D, Zhang M
OncoTargets and Therapy 2019, 12:2079-2088
Published Date: 19 March 2019
High SRPX2 protein expression predicts unfavorable clinical outcome in patients with prostate cancer
Zhang M, Li X, Fan Z, Zhao J, Liu S, Zhang M, Li H, Goscinski MA, Fan H, Suo Z
OncoTargets and Therapy 2018, 11:3149-3157
Published Date: 28 May 2018